FIA
KRYS icon

FNY Investment Advisers’s Krystal Biotech KRYS Stock Holding History

FNY Investment Advisers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21,148
Closed -$1.27M – 917
2020
Q4 		$1.27M Buy
21,148
+10,000
+90% +$499K 0.35% 70
2020
Q3 		$479K Buy
+11,148
New +$484K 0.2% 105

Other funds holding KRYS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FNY Investment Advisers's KRYS Position: Q1 2021 in Review

FNY Investment Advisers sold out of Krystal Biotech (KRYS) in Q1 2021, closing a stake of 21,148 shares — an estimated $1.27M sold.

FNY Investment Advisers first reported a position in KRYS in Q3 2020 and held it in 2 quarters. The position peaked at $1.27M in Q4 2020. 113 funds tracked by Wall St. Rank hold KRYS as of Q1 2021.

  • FNY Investment Advisers reported no remaining Krystal Biotech position as of Q1 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 21,148 Krystal Biotech shares in Q1 2021, an estimated $1.27M.
  • FNY Investment Advisers first reported a position in Krystal Biotech in Q3 2020 and held it in 2 quarters.
  • FNY Investment Advisers's Krystal Biotech position peaked at $1.27M in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2021.

Based on FNY Investment Advisers's 13F filing for Q1 2021, filed 12 Apr 2021.